Literature DB >> 23731983

The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe.

Rossella E Nappi1, Lars-Åke Mattsson, Michèle Lachowsky, Ricardo Maamari, Annamaria Giraldi.   

Abstract

OBJECTIVES: CLOSER investigated how postmenopausal vaginal atrophy ('vaginal discomfort') affects relationships between women and their partners. STUDY
DESIGN: CLOSER involved postmenopausal women (55-65 years) with vaginal discomfort, and male partners of women with the condition. MAIN OUTCOME MEASURES: Structured questionnaire collecting information on impact of vaginal discomfort and local oestrogen treatment on intimacy and relationships, and symptoms and impact of menopause.
RESULTS: 1600 women and 1600 men from Northern Europe and 1000 women and 1000 men from Southern Europe were included. Worry that vaginal discomfort would never go away was expressed by 28% and 38% of women in Northern and Southern Europe, respectively (p<0.05), while 21% and 27% worried that vaginal discomfort would ruin their future sex life (p<0.05). Half of women who avoided intimacy worried about painful sex. Among men, 86% wanted their partner to talk about symptoms; two-thirds felt comfortable with this. In Northern and Southern Europe, 15% and 11% of men, respectively, feared that discussing vaginal discomfort would ruin intimacy, while 29% and 19% believed that vaginal discomfort was a big problem in their sex life. Men with partners who avoided intimacy recognised that worry about painful sex was the main reason. Vaginal discomfort impaired self-esteem and emotional wellbeing among women, while local oestrogen treatment improved relationships, particularly in Southern Europe.
CONCLUSIONS: Vaginal discomfort impairs quality of life in postmenopausal women and their partners. Southern European women were generally more worried about long-term effects on their relationship, and were more likely to report benefits after treatment.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Local oestrogen therapy; Male partner; Menopause; Relationships; Vaginal atrophy; Vaginal discomfort

Mesh:

Substances:

Year:  2013        PMID: 23731983     DOI: 10.1016/j.maturitas.2013.05.003

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  8 in total

1.  Personal and Clinical Vaginal Lubricants: Impact on Local Vaginal Microenvironment and Implications for Epithelial Cell Host Response and Barrier Function.

Authors:  Ellen M Wilkinson; Paweł Łaniewski; Melissa M Herbst-Kralovetz; Rebecca M Brotman
Journal:  J Infect Dis       Date:  2019-11-06       Impact factor: 5.226

2.  Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders.

Authors:  Elisabeth A Erekson; Fang-Yong Li; Deanna K Martin; Terri R Fried
Journal:  Menopause       Date:  2016-04       Impact factor: 2.953

3.  Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries.

Authors:  Ginger D Constantine; Shelli Graham; Cathy Clerinx; Brian A Bernick; Mitchell Krassan; Sebastian Mirkin; Heather Currie
Journal:  Post Reprod Health       Date:  2016-02-18

4.  Women's knowledge about the genitourinary syndrome of menopause: adherence to its treatments in the COVID-19 era in a sample of them: COMEM-GSM study.

Authors:  Laura Baquedano Mainar; Sonia Sánchez Méndez; Peña Dieste Pérez; Mónica Hernández Aragón; Nicolás Mendoza Ladrón de Guevara
Journal:  BMC Womens Health       Date:  2021-11-30       Impact factor: 2.809

5.  Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.

Authors:  R E Nappi; S Palacios; N Panay; M Particco; M L Krychman
Journal:  Climacteric       Date:  2015-11-19       Impact factor: 3.005

6.  Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.

Authors:  N Bruyniks; R E Nappi; C Castelo-Branco; T J de Villiers; J Simon
Journal:  Climacteric       Date:  2015-11-19       Impact factor: 3.005

7.  Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.

Authors:  James A Simon; Corrado Altomare; Susannah Cort; Wei Jiang; JoAnn V Pinkerton
Journal:  J Womens Health (Larchmt)       Date:  2017-10-24       Impact factor: 2.681

Review 8.  Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women.

Authors:  Rossella E Nappi; Ellis Martini; Laura Cucinella; Silvia Martella; Lara Tiranini; Alessandra Inzoli; Emanuela Brambilla; David Bosoni; Chiara Cassani; Barbara Gardella
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-21       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.